Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated β-amyloid peptides

Neurodegenerative Diseases

Volumn 5, Issue 5, 2008, Pages 268-276

  Hoglund K ^a,d   Hansson, O ^b   Buchhave, P ^b   Zetterberg, H ^a   Lewczuk, P ^c   Londos, E ^b   Blennow, K ^a   Minthon, L ^b   Wiltfang, J ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Department of Neuroscience and Physiology   (Sweden)

Author keywords

Amyloid; Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Mild cognitive impairment; Peptide pattern

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 44649183443     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000119457     Document Type: Article

References (35)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
2. Tierney MC, Szalai JP, Snow WG, Fisher RH, Nores A, Nadon G, Dunn E, St George-Hyslop PH: Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661-665.
3. Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet 2006;368:387-403.
4. Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.
5. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-680.
6. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
7. Ivanoiu A, Sindic CJ: Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 2005;11:32-39.
8. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A: Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002;59:1729-1734.
9. Zetterberg H, Wahlund LO, Blennow K: Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 2003;352:67-69.
10. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Evaluation of CSF-tau and CSFA-beta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379.
11. Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H: Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 2001;172:433-436.
12. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Moller HJ, Blennow K, Buerger K: Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-710.
13. Maruyama M, Matsui T, Tanji H, Nemoto M, Tomita N, Ootsuki M, Arai H, Sasaki H: Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol 2004;61:716-720.
14. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, Schmidt B, Klafki HW, Maler M, Dyrks T, Bienert M, Beyermann M, Ruther E, Kornhuber J: Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem 2002;81:481-496.
15. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Ruther E, Kornhuber J, Annaert W, De Strooper B, Saftig P: Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem 2001;276:42645-42657.
16. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler JM, Ruther E, Kornhuber J, Wiltfang J: The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 2003;17:1291-1296.
17. Höglund K, Syversen S, Lewczuk P, Wallin A, Wiltfang J, Blennow K: Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease. Exp Brain Res 2005;164:205-214.
18. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Ruther E, Kornhuber J, Otto M, Wiltfang J: CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006;129:1177-1187.
19. Fukuyama R, Mizuno T, Mori S, Nakajima K, Fushiki S, Yanagisawa K: Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur Neurol 2000;43:155-160.
20. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J: Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 2006;52:332-334.
21. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J: Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/ Abeta40 ratio and total tau. Neurobiol Aging 2004;25:273-281.
22. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, Mc-Culloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller H, Davies P, Hampel H: CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002;59:627-629.
23. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ: Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004;61:59-66.
24. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM: Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004;56:670-676.
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, American Psychiatric Association, 1987.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
27. Wiltfang J, Arold N, Neuhoff V: A new multiphasic buffer system for sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins and peptides with molecular masses 100,000-1,000, and their detection with picomolar sensitivity. Electrophoresis 1991;12:352-366.
28. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K: Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345.
29. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-862.
30. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866.
31. Mehta PD, Pirttila T: Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease. Neurodegener Dis 2005;2:242-245.
32. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD: Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 2005;58:139-142.
33. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2005;102:2273-2276.
34. Sjogren M, Vanderstichele H, Ågren H, Blennow K: Tau and Aβ42 levels in cerebrospinal fluid from health adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47:1776-1781.
35. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K: Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999;273:5-8.